Teva Pharmaceutical Industries (TEVA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

TEVA · Stock Price

USD 36.34+18.27 (+101.11%)

Market Cap: $42.7B

Historical price data

Market Cap: $42.7BPipeline: 9 drugsPatents: 20Founded: 1901Employees: ~37,000HQ: Petah Tikva, Israel

Sector Ranking#69 in Small Molecule Drugs

Overview

Teva Pharmaceutical Industries is executing a successful 'Pivot to Growth' strategy, transitioning from a generics-centric model to an innovation-driven biopharmaceutical company. This shift has yielded three consecutive years of revenue growth, driven by its specialty portfolio in CNS disorders and a burgeoning biosimilars pipeline. The company's integrated model, spanning complex generics, API manufacturing, and novel drug development, provides a durable competitive moat and positions it to address both affordability and unmet medical needs globally.

NeuroscienceImmunology

Technology Platform

Integrated platform spanning complex generic drug formulation, large-scale API manufacturing, biosimilar development, and novel drug R&D focused on neuroscience and immunology.

Pipeline

9

9 drugs in pipeline

Drug	Indication	Stage
Laquinimod + Placebo	Relapsing Remitting Multiple Sclerosis	Phase 2
TV-1106 + somatropin	Growth Hormone-Deficiency	Phase 2
40 mg glatiramer acetate + Placebo	Amyotrophic Lateral Sclerosis	Phase 2
Hydroxychloroquine (HCQ) + Azithromycin (Azithro) + Placebo ...	COVID-19	Phase 2
cytarabine + omacetaxine mepesuccinate + decitabine	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome	Phase 2

Opportunities

The global biosimilars market offers a multi-billion dollar growth avenue as major biologic drugs lose exclusivity.

Additionally, deep expertise in complex neuroscience disorders like schizophrenia and movement disorders allows Teva to target high-unmet-need niches with limited competition and strong pricing power.

Risk Factors

Teva faces persistent pricing pressure and competition in its core generics business, which could impact cash flow.

The company's growth strategy is also heavily reliant on successful clinical development and commercialization of its late-stage pipeline candidates, introducing significant execution and regulatory risk.

Competitive Landscape

In generics and biosimilars, Teva competes on scale and complexity against giants like Viatris, Sandoz, and Amgen. In specialty neuroscience and immunology, it contends with large pharma (e.g., AbbVie) and biotech innovators, differentiating through legacy CNS expertise and an integrated commercial model.